Custom Search

Topotecan News

Oral Hycamtin® May Offer Oral Therapy for Recurrent Non–Small Cell Lung Cancer

Researchers from Europe, South Africa and Canada have reported that oral Hycamtin (topotecan) and intravenous Taxotere® (docetaxel) are of equal benefit for the treatment recurrent non–small cell lung cancer (NSCLC). The details...

Hycamtin® Approved for Advanced Cervical Cancer

GlaxoSmithKline’s chemotherapy agent Hycamtin (topotecan) has received FDA approval for an expanded indication to include treatment of recurrent cervical cancer in combination with Platinol® (cisplatin).

Small Cell Lung Cancer

Lung cancer is the leading cause of cancer deaths among Americans, accounting for almost a third of all cancer deaths. There are two major types of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer...

Supplemental New Drug Application Accepted for Hycamtin® in Treatment of Cervical Cancer

The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for GlaxoSmithKline’s chemotherapy agent Hycamtin (topotecan HCL) for Injection. The FDA has also granted priority review status...

Hycamtin cleared for lung cancer in Europe

The intravenous formulation of GlaxoSmithKline's Hycamtin has become the first drug in Europe to be approved for patients with small cell lung cancer who relapse after first-line treatment.

Displaying results 11 to 15 out of 16

< Previous





Next >

Use of this site is subject to the following terms of use